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EGFR MUTATED LUNG CANCER: CURRENT THERAPIES AND  
 
POTENTIAL FUTURE TREATMENTS 
 
 
ANDREW POLIO 
 
 
ABSTRACT 
 
Lung cancer is the leading cause of cancer related deaths in the United States, with an 
estimated 158, 040 deaths in 2015, accounting for 27% of all cancer deaths. Recent 
research has identified several important molecular driver oncogenes, including 
epidermal growth factor receptor (EGFR). EGFR is encoded by exons 18-21, each of 
which harbor specific mutations within the tyrosine kinase domain. These mutations can 
drive cell growth, proliferation, and survival, resulting in the formation of non-small cell 
lung cancer. The development of EGFR tyrosine kinase inhibitors, allows the targeting of 
these specific mutations without the toxicity normally associated with standard 
chemotherapy. Unfortunately, inevitably resistance to therapy manifests, requiring a 
change in therapy and adding complexity to treatment decision making for clinicians and 
patients alike. Through a comprehensive examination of current literature, this review 
will establish a standard for first line, targeted treatment for specific genetic mutations 
within the EGFR gene, as well as address treatment options once resistance to first-line 
therapy inevitably develops.       
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INTRODUCTION 
 Lung cancer is the leading cause of cancer related deaths in the United States, 
with an estimated 158, 040 deaths in 2015, accounting for 27% of all cancer deaths. Early 
detection of lung cancer is difficult with only 15% of lung cancers diagnosed at a 
localized stage (American Cancer Society, 2015). Once lung cancer has reached a locally 
advanced or metastatic stage, chemotherapy is usually prescribed. Unfortunately, 
chemotherapy has little success in treating this disease, with a median time to progression 
of 4 to 6 months and a median overall survival of 10 to 12 months (Melosky, 2014). 
Despite advances in clinical therapies, the 1 and 5-year survival rates for lung cancer 
patients remain at a discouraging 44% and 17%, respectively (American Cancer Society, 
2015). Additional research is required to establish concrete working knowledge of the 
molecular drivers of this disease and novel therapies to increase overall survival rates for 
patients. 
 Lung cancer is divided histologically into two groups, small cell lung cancer and 
non-small cell lung cancer, with NSCLC predominating with an occurrence of 83% 
(Ibid). NSCLC can be further largely be categorized into squamous cell carcinoma, large 
cell carcinoma, and adenocarcinoma (Non-Small Cell Lung Cancer Treatment, 2015). 
NSCLC, regardless of histological subtype, has proven to be challenging to treat and 
prevent. This is because NSCLC is one of the more genetically aberrant cancers (Li, 
2015). Thankfully, this biologic characteristic of NSCLC also allows researchers to 
divide NSLC into smaller subsets based on the molecular drivers of tumor growth, 
providing multiple targets for novel drugs. Indeed, over the last decade, with advances in 
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genetic sequencing techniques and sensitivity, there has been expansive discovery of a 
subset of driver mutations in NSCLC (Figure 1). These subsets are divided into molecular 
subgroups defined by specific driver mutations occurring in several oncogenes, including 
AKT1, ALK, BRAF, ROS1, HER2, KRAS, MEK1, NRAS, PIK3CA, RET, and EGFR 
(Lovly, 2015). The discovery of EGFR mutations in patients with NSCLC has led to the 
development of effective therapies for this subgroup population, confirming targeted 
therapies as worthy of further exploration for other driver mutations for lung cancer 
patients.   
 
Figure 1: NSCLC Identified Mutations. A depiction of all currently known NSCLC 
mutations compared to what was known in 2003. It illustrates the discovery of targetable 
genes over the past decade. Adapted from LCFAmerica. 
 
 Lung cancers that harbor EGFR activating mutations account for a significant 
proportion of NSCLC diagnoses, especially in Asian populations and non-smokers. The 
ability to offer a viable treatment course will be important in extending the overall 
survival of this patient population. It has been established there are several different types 
of EGFR mutations; with evidence showing different subtypes of this mutation should be 
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treated uniquely, with different treatment approaches. It is well established identifying 
EGFR mutations can predict which patients will benefit from treatment with TKIs (Mok 
et al., 2009, Douillard et al., 2009). EGFR mutational testing has, therefore, become 
standard procedure for this patient population. This has led to a coordinated effort to 
establish which EGFR mutations are sensitizing to TKI treatment, in order to better 
inform patients and clinicians alike as to what therapy to use when confronted with this 
diagnosis. While common mutations have been extensively studied, and a first-line 
standard has been established, there still remains debate over the correct course of 
treatment for these patients. A first-line standard of care has yet to be determined 
conclusively for patients whose tumors harbor rarer EGFR mutations. Additionally, there 
remains debate of how to treat patients in advanced line settings, especially once tumors 
have acquired resistance. To this end, there is current excitement about third-generation 
TKIs, currently undergoing clinical trials, and their ability to target acquired resistance 
mutations. 
 In this review, current literature will be analyzed to gain a better understanding of 
EGFR mutations as a whole, review current and potential future therapies for this patient 
population, and establish a comprehensive protocol for the treatment of these patients in 
order to best preserve quality of life and extend overall survival.  
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EGFR MUTATIONS 
I. History of the EGFR Gene 
 
 In 1962, Stanley Cohen, following work on the protein, nerve growth factor 
(NGF), isolated another protein that stimulated proliferation of epithelial cells, and called 
it epidermal growth factor (EGF) (Gschwind et al., 2004). Over a decade later, Graham 
Carpenter confirmed the existence of specific binding receptors for EGF (EGFR) on the 
surface of cells, using 125I-labelled EGF and fibroblasts from various species. The 
development of molecular cloning in the mid-1970s eventually led to the sequencing and 
determination of EGF’s amino acid sequence. In 1980 researchers showed increased EGF 
kinase activity in A-431 human epidermoid carcinoma cells involved the phosphorylation 
of tyrosine residues (Ushiro, 1980). Indeed, throughout the 1980s academic and industry 
research indicated a role of deregulated EGFR in human cancers. Further research 
throughout the 1980s would characterize EGF more fully and elucidate several of its 
downstream signaling partners (Kamata, 1984). Throughout the 1990s, using 
crystallographic studies, increased detail was provided to specifically to how the 
dimerization is regulated through receptor binding.  
 Screening of cDNA libraries using EGFR probe actually showed that EGFR 
belongs to a family of closely related proteins. The EGFR gene belongs to a family of 
tyrosine kinase receptors that includes EGFR (HER1), HER2, HER3, and HER4. The 
binding of epidermal growth factor induces a conformational change, which leads to 
dimerization, phosphorylation, and activation of the receptor. Activation of the receptor 
triggers multiple downstream signal cascades within the cell, which include PI3K-AKT-
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mTOR and the RAS-RAF-MEK-ERK pathway (Figure 2)(Zhang et al., 2008). These 
signal cascades lead to profuse cellular responses. These cellular responses include 
increased cell proliferation, motility, resistance to apoptosis, and invasion. Mutations in 
EGFR result in constant activation of these pathways and subsequent tumorgenesis.  
 
 
Figure 2: Pathways Activated by EGFR binding. Scheme of RAS-RAF-MEK-ERK 
and PI3K-AKT-mTOR pathways activated by binding to EGFR receptor. “K” denotes the 
tyrosine kinase domain. Adapted from Lovly et al., 2015. 
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 In the early 1990s it was established a higher rate of EGFR expression was found 
in tumor tissue than in normal, non-cancerous tissues, including NSCLC (Dittadi et al., 
1991, Palazzo et al., 1993). This signified EGFR as a potential therapeutic target and 
initiated the clinical development of EGFR tyrosine kinase inhibitors (TKI). TKIs work 
by interrupting or turning off cell signaling pathways and inducing apoptosis. The initial 
development of TKIs culminated in the production of gefitinib (trade name Iressa), by 
Astrazeneca. Gefitinib inhibited cancer growth by binding selectively to the ATP-binding 
site of the enzyme, thus interrupting cell signaling to induce activation of the anti-
apoptotic Ras signal transduction pathway. In a phase I trial, Gefitinib demonstrated a 
response in patients with solid cancers likely to express EGFR mutations, with a tolerable 
toxicity profile (Ranson et al., 2002). Additional studies showed a response in patients 
with NSCLC, after progression on standard chemotherapy, with both a radiographic and 
symptomatic response (Kris, et al., 2003). Although a response was only observed in a 
fraction of NSCLC patients, due to the quickness and significance of the response rates, 
gefitinib received accelerated approval by the FDA in May 2003 as a monotherapy for 
patients of patients with locally advanced or metastatic NSCLC post-progression on 
standard chemotherapy. At the time, while there had been established first and second 
chemotherapy regimens for this group of patients, the need for third therapy had not been 
met. Gefitinib was thus approved for use in a third line setting (Cohen, 2004). Despite its 
approval, it was still unknown at the time, why only a fraction of patients with NSCLC 
responded to gefitinib therapy. Further investigations were conducted in order to 
elucidate the reasoning behind this phenomenon.  
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 In 2004, two groups independently showed EGFR mutations were potentially 
sensitized to treatment with the tyrosine kinase inhibitor, gefitinib (Paez et. al, 2004, 
Lynch et. al, 2004). Each group independently identified patients who responded to 
treatment with gefitinib and patients who did not respond to treatment, as defined by 
radiographic criteria. Within each group, patients who had pre-treatment tissue available 
were selected. Tumor tissue was subsequently sequenced and analyzed. An 
overwhelming majority of patients who responded to Gefitinib treatment harbored 
mutations in the tyrosine kinase domain of the EGFR gene. A majority of patients 
without a response, did not harbor these mutations. Furthermore, patients who exhibited 
EGFR mutations had matched normal tissue analyzed. This showed a lack of EGFR 
mutations, demonstrating conclusively these are somatic mutations. Both groups’ 
findings demonstrate EGFR activating mutations confer sensitivity to gefitinib therapy. 
Discovering this molecular correlation to a response to a TKI provided immediate and 
important clinical implications, as patients who harbored these activating mutations 
would gain significant benefit from treatment with targeted therapy. This discovery 
prompted additional investigation into EGFR gene mutations and potential therapies for 
patients who harbor these mutations. 
 EGFR mutations are located with exons 18 to 21, which encode a portion of the 
tyrosine kinase domain. Although multiple mutations have been identified, a vast 
majority of EGFR mutations are either exon 19 deletions or exon 21 L858R mutations, 
40 and 45% respectively. Interestingly, despite one exception, mutations within exon 20 
are non-sensitizing to TKI therapy (figure 3). Furthermore, these mutations have a higher 
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prevalence in non-smoking, Asian women, with adenocarcinoma histology (figure 
4)(Mitsudomi et al., 2007). Many additional groups have confirmed the relationship 
between EGFR mutation status and the described clinical background. It has also been 
noted that EGFR mutations are exclusive with KRAS and ALK mutations (Jänne et al., 
2005). 
 
 
Figure 3: Location of EGFR mutations. This schematic represents the mutations found 
within exons 18-21. It also indicates if the identified mutations are sensitized to TKI 
therapies. Adapted from Lovly et al., 2015 
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Figure 4: Incidence of EGFR mutations in populations of various clinical 
backgrounds. Data collected from literature showing the incidence of EGFR mutations, 
found in 559 mutations in 2880 lung cancer patients. Adapted from Mitsudomi, 2006 
 
 As technologies and research continues inquiry into the molecular landscape of 
EGFR mutated lung cancer, the picture becomes increasingly more complex. Subsequent 
research has elucidated additional mutations within the EGFR gene, along with resistance 
mutations that thwart treatment with first and second generation TKIs. Third generation 
TKIs, currently undergoing clinical trials, seem to address these resistance mutations, but 
for how long before additional resistance develops as well as the full clinical implications 
of these new drugs remains to be seen. Much work is still required to elucidate a 
comprehensive, working knowledge of EGFR mutations and their resistance 
mechanisms, which will provide gateways to the development of treatment options that 
will procure effective and sustained responses for patients coping with this disease. 
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TREATMENT OF SPECIFIC EGFR MUTATIONS 
As research continues investigating EGFR mutations, it has become clear there is a 
diverse range of specific EGFR mutations within the coding region for the tyrosine 
kinase domain of this gene. It has also become clear that specific mutations will dictate 
the treatment patients should receive. While a majority of these mutations are sensitized 
to treatment with TKIs, there is a documented degree of response to TKIs with each 
mutation (figure 5). Additionally, some mutations are not sensitized to treatment with 
TKIs and require alternative measures (Mitsudomi et al., 2006).  
 
Figure 5: Response rates of specific EGFR mutations to TKI therapy. This 
demonstrates a gradient of response, with exon 19 deletions conferring the highest 
sensitivity. Adapted from Mitsudomi et al., 2006.  
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It is therefore important, once a patient’s mutational status is determined, to tailor 
treatment according the specific mutation a patient’s tumor harbors. The development of 
resistance or histological transformation for patients previously treated with TKIs also 
complicates the situation. Table 1 lists suggested treatments for TKI naïve patients as 
well as patients who acquire resistance to treatment. This underscores the importance of 
obtaining repeat biopsy samples and repeated sequencing of patient tissue, as the results 
can help dictate what therapy patients should receive during each course of their 
treatment.  
Table 1: Summary of suggested therapy for TKI naïve patients and patients with 
acquired resistance to TKI therapy. Based on current literature reviewed. 
 
 
Tyrosine	  Kinase	  Inhibitor	  Treatment	  Naive	  
Mutation	   Suggested	  Therapy	  
Exon 18 Mutations	   Irreversible TKI (afatinib, neratinib)	  
Exon 19 Deletion Mutations	   Reversible TKI (erlotinib, gefitinib)	  
Exon 19 Insertion Mutations	   Reversible TKI (erlotinib, gefitinib)	  
Exon 20 Insertion	   Standard platinum-doublet chemotherapy 
or clinical trial (AUY922)	  
Exon 20 A763_Y764insFQEA Insertion 	   Reversible TKI (erlotinib, gefitinib)	  
Exon 21 L858R Mutations	   Reversible TKI erlotinib, geftinib)	  
Exon 21 L861Q Mutations	   Irreversible TKI (afatinib, neratinib)	  
T790M Mutations	   Standard chemotherapy and germline 
testing	  
Acquired	  Resistance	  to	  TKI	  Therapy	  
Mutation	   Suggested	  Therapy	  
T790M Mutations	   Third-generation TKI (AZD9291, 
rociletinib)	  
MET Amplification	   Combination therapy, EGFR inhibitor and 
MET inhibitor (AZD9291, savolitinib)	  
Transformation to SCLC	   Platinum / etoposide chemotherapy	  
Other Resistance Mutations	   Platinum-doublet chemotherapy	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I. Exon 18 G719X Mutations: 
 
 Mutations within the exon 18 coding region are in the observed minority of EGFR 
mutations, consisting an estimated 3% of all reported cases (Mitsudomi et al., 2010). The 
most common mutation is a point mutation, located in the nucleotide-binding loop, 
replacing a glycine with another amino acid at position 719. Multiple amino acid 
substitutions have been described, resulting in the common notation of this gene 
mutation, G719X. The amino acid substitutions described in the literature are cysteine 
(G719C), aspartic acid (G719D), serine (G719S), valine (G719V), and alanine (G719A). 
G719A, G719C, and G719S are observed as most frequent, with prevalence of 0.6%, 
0.3%, and 0.5% of all EGFR mutated NSCLC, respectively (Seigelin and Borczuk, 
2013).  
 Current understanding of exon 18 mutations suggests they are sensitive to 
treatment to TKIs. Locatelli-Sanchez et al. collected 793 NSCLC tumor samples from 
753 patients, analyzing for EGFR mutations of exon 18 to 21 by direct sequencing, 
identifying 133 mutations from 124 patients. This large sample retrospective study aimed 
to assess outcomes of patients with this mutation. Of the 133 identified EGFR mutations, 
10 (7.5%) were identified in 6 patients as located within exon 18. Patients treated with 
TKIs experienced tumor regression, suggesting exon 18 mutations are responsive to 
inhibition with TKIs (Locatelli-Sanchez et al., 2013). This observation has been 
previously investigated and confirmed by other groups (Takano et al., 2005, Han et al., 
2005).  
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 Despite response to TKI treatment Locatelli-Sanchez et al. note patients with exon 
18 mutations have a worse overall survival compared those patients exhibiting exon 19 or 
21 mutations. The diminished response of these patients to targeted therapy may be due 
to a differential sensitivity of various EGFR mutations to TKI therapy as described by 
Jiang et al. The group demonstrated, although exon 21 L858R and exon 18 G719S 
mutations display similar ligand-independent activation of EGFR signaling, gefitinib 
inhibits L858R with an approximate 10-fold higher sensitivity. They postulate this is due 
to the location of the G719X mutation.  
 Gefitinib acts competitively with ATP for binding within the ATP binding loop, 
where the G719X mutation is located. The substitution of glycine, a small amino acid, 
with a larger amino acid, such as serine or aspartic acid, could drastically disrupt the 
structure or the binding domain, inducing a less favorable confirmation for gefitinib 
binding (Jiang et al., 2005). Watanabe et al. confirmed the lesser response of G719X 
mutations to targeted therapy after analyzing 225 patients who had received gefitinib at 
any treatment line (Watanabe et al., 2014). The group’s findings suggest for patient’s 
harboring rare EGFR mutations, first line chemotherapy over targeted therapy may be an 
effective treatment strategy. Of further note, a trial investigating the pan-ErbB inhibitor 
TKI, neratinib, showed activity against the G719X mutation. Sequist et al. investigated 
the activity of neratinib against T790M mutations, a resistance mutation that develops in 
some patients after treatment with targeted therapy. The group showed neratinib has low 
clinical activity against TKI naïve patients and patients who had a history of TKI 
treatment. However, the group notes of the 4 patients harboring G719X mutations, 3 
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experienced partial responses, with the 4th patient experiencing stable disease lasting 40 
weeks (figure 6)(Sequist et al., 2010). This finding concurs with previous preclinical 
models, which note neratinib may be a more potent inhibitor of point mutations, such as 
G719X, versus deletions (Yuza et al., 2007). Similar to neratinib, is afatinib, another 
irreversible covalent inhibitor of EGFR and HER2. Afatinib has demonstrated efficacy 
against EGFR sensitizing mutations and may also be effective therapy for patients 
harboring these mutations (Joshi et al., 2015). It has been recently demonstrated cells 
transfected with G719X mutations respond at a substantially higher rate to afatinib and 
neratinib than to first generation TKIs (Kobayashi, 2015). The results published by 
Sequist et al. demonstrate the importance of complete genetic testing to be performed in 
indicated patient populations, especially in the context of clinical trial testing.   
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Figure 6: Plot of best response for patients previously exposed to TKI treatment on 
neratinib. The best response of patients shows the efficacy of neratinib on patients 
harboring G719X mutations. It underscores the finding of Yuza et al., as most patients 
with deletion mutations did not receive benefit from treatment with neratinib. Adapted 
from Sequist et al., 2010. 
 
 The paucity of G719X mutations in exon 18 occurring in patients with NSCLC, 
make it difficult to generate enough data to form concrete discoveries about the best 
treatment for these patients. Most published information of these mutations occurs in 
extremely small numbers or as case reports, the results of which are many times 
controversial. Current research shows G719X mutations are sensitizing to treatment with 
TKIs, despite evidence that the response is diminished in relation to other EGFR 
mutations. Targeted therapies, therefore, may prove beneficial to this patient group. 
However, it should be noted, it has been postulated by some groups, TKIs may not be the 
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most effective therapy for this patient population and until more robust data is published, 
they argue chemotherapy is the adequate therapy. With the current lack of data available 
for this subset of patients, it has been suggested these patients be assessed individually, 
rather than a group (Karachaliou et al., 2015). Compilation of data from multiple 
databases and various institutions experiences with this rare mutation will further 
elucidate the clinical course necessary for the treatment of this mutation. Until then, the 
question of how to most effectively treat these patients will go unanswered. This further 
investigation will enable researchers to further define a standard of treatment that will 
provide a better quality of life and extended overall survival. 
II. Exon 19 Mutations: 
 
 Mutations occurring in exon 19 of the EGFR gene constitute one of the most 
common somatic mutations within EGFR. Two major types of exon 19 mutations have 
been identified to date: exon 19 deletions and exon 19 insertions. Exon 19 deletions 
comprise the majority of the mutations originating from this exon, with an occurrence 
rate of approximately 48%, while exon 19 insertions are much more rare, with an 
occurrence of only approximately 1% (Lovly et al., 2015, He et al., 2012). Comprising of 
almost half of all reported EGFR mutations, exon 19 deletions therefore have been 
extensively investigated. 
IIa. Exon 19 Deletions: 
 
 Deletion mutations occurring in exon 19 are some of the more frequent noted in 
patients with NSCLC. Exon 19 deletions are located in the gene region responsible for 
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encoding the C-helix portion of the tyrosine kinase domain. Multiple deletions have been 
described, with the majority encompassing codons L747 to E749, also known as the LRE 
fragment, located between strand β3 and the αC helix (Chung et al., 2012)(figure 7). This 
fragment contributes to hydrophobic residues, which stabilize the inactive state of the 
protein. Mutations to this area can disrupt this stabilization, thus leading to an ever-active 
confirmation.
 18 
 
 
Figure 7: Structure of the EGFR tyrosine kinase domain, shown here bound to 
erlotinib. The domain consists of a C-lobe and N-lobe. The ATP binding site is adjacent 
to the P-loop, shown here bound to erlotinib. Various EGFR mutation locations are 
highlighted with black arrows. Adapted from Yasuda et al., 2012 
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 The most frequent mutations to this area are delE746-A750, delL747-P753insS, 
delL747-A750insP, and delL747-T751, with reported rates of occurrence of 66.1%, 
56.8%, 4.0%, and 3.7%, respectively (Ibid). Deletion mutations have also been 
discovered that do not contain the region L747-E749, most notably, delS752-I759.   
 Exon 19 deletions have been extensively described in the literature due to their 
high occurrence in patients with EGFR mutant tumors.  Various groups have 
demonstrated, in vitro, exon 19 deletions are sensitive to inhibition by TKIs, which 
inhibit autophosporylation at 10-100 fold lower concentrations of gefitinib needed to 
inactivate wild type EGFR (Ono et al., 2004, Paez et al., 2004). Exposing mutant cell 
lines to therapeutic doses of gefinitib showed inhibition of EGFR and provided validation 
for further clinical exploration. This led to a plethora of studies exploring the efficacy of 
TKIs as suitable treatment for patients with exon 19 deletions.  
 It has now been well-established patients exhibiting exon 19 deletions should 
receive TKI as first-line therapy. One such study to establish this is the OPTIMAL study. 
A phase III open label randomized study, it compared the efficacy and tolerability of 
first-line erlotinib treatment versus carboplatin plus gemcitabine in patients with stage 
IIIB or IV cancer harboring exon 19 deletion or exon 21 L858R activating mutations. 
This study demonstrated this patient population benefits from erlotinib therapy in the 
first-line setting with a median progression free survival significantly longer than that of 
the chemotherapy alone arm (13.1 [95% CI 10.58-16.53] versus 4.6 [4.21-5.42] months, 
p<0.0001)(figure 8)(Zhou et al., 2011). Additionally, the study showed erlotinib to be 
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substantially more tolerable, with a lower association to grade 3 and 4 toxicities than 
standard chemotherapy.  
 
 
Figure 8: Progression free survival in both treatment groups. Patients who received 
erlotinib in the first-line setting fared significantly better than their counterparts who 
received chemotherapy alone. Additionally, they experienced far less toxicity. Adapted 
from Zhou et al., 2011. 
 
While this study’s participants comprised of solely Asian patients, various other groups 
have confirmed this findings in other patient populations (Rosell et al., 2012, Jänne et al., 
2012). The EURTAC study, a pivotal open-label, randomized phase III trial, is the basis 
for the FDA approval of erlotinib in the first-line setting for patient with sensitizing 
EGFR mutations. Rosell et al., evaluated 173 patients, identified as chemotherapy naïve, 
exhibiting sensitizing EGFR mutations, stratified by EGFR mutation type and ECOG 
 21 
performance status. Patients were randomized in a 1:1 ratio to treatment with erlotinib or 
a chemotherapy regimen and followed for PFS. Median PFS was found to be 9.7 months 
in the erlotinib group versus 5.2 months in the standard chemotherapy group (hazard ratio 
0·37, 95% CI 0·25–0·54; p<0·0001)(figure 9)(Rosell et al., 2012). These results were 
pivotal in determining FDA approval for erlotinib in the first line setting for patients with 
sensitizing mutations. 
 
Figure 9: Progression free survival for each treatment group. This Kaplan-Meier plot 
of progression free survival based on radiological evidence demonstrates erlotinib as a 
more efficacious treatment for this patient population. Adapted from Rosell, 2012. 
 
 The results of these two studies has been confirmed by numerous trials and 
analyses conducted by various groups (Gao et al., 2012, Lee et al., 2013, Mok et al., 
2009, Mitsudomi et al., 2010, Maemondo et al., 2010). Interestingly, afatinib has also 
proven to be a viable treatment option in the first-line setting.  
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 The LUX-Lung 3 trial, a large, open-label randomized phase III study 
investigated afatinib versus pemetrexed and cisplatin combination therapy as a first-line 
treatment option for patients with advanced adenocarcinoma, with EGFR activating 
mutations. 345 patients were randomized in a 2:1 (afatinib:chemotherapy) ratio and 
followed for PFS. 308 patients harbored common mutations and experienced a median 
PFS of 13.6 months compared to 6.9 months (HR=0.47, p<0.0001)(Yang et al., 2012). 
Similar activity was demonstrated in the LUX-Lung 2 study (Yang et al., 2012). In 
response to the results of the LUX-Lung 3 trial, in 2013, afatinib was approved for use in 
the first line setting for patients with exon 19 deletion and exon 21 mutations. 
 Comparison of gefitinib, erlotinib, and afatinib in a meta-analysis published in 
2014, yielded no statistically significant differences (Haaland et al., 2014). Despite these 
results, erlotinib remains the standard treatment course for patients with exon 19 
deletions in the first-line setting. This may be due to its already widespread use in this 
setting or its toxicity profile, which, when compared to afatinib, tends to be more 
tolerable. Most influential perhaps, however, is the fact that afatinib is an irreversible 
pan-HER inhibitor. This characteristic enables afatinib some activity against T790M 
resistance mutations, which develops post-progression in a significant percentage of 
patients. It was thought this would enable afatinib to be a potent second-line therapy for 
patients who progress on first-line targeted therapies. It has since been demonstrated, 
however, response to afatinib in the second-line is modest at best, with a substantial 
toxicity profile (Joshi et al., 2015). Therefore, afatinib is not recommended in the second-
line setting as a monotherapy.  
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 While exon 19 deletions that encompass the LRE fragment are responsive to TKI 
therapy, non-LRE deletions have been shown to have a worse response rate to targeted 
therapies. Chung et al., enrolled patients with exon 19 deletions and evaluated patients 
treated with TKIs for RR, PFS, and OS. They stratified patients based on the specific 
deletion their tumor harbored. Their analysis shows varying RR based on the specific 
deletion mutation (Table 1). Of all the deletions analyzed, non-LRE deletions 
demonstrated the lowest RR, with a response rate of 42.9% compared to 76.9% for 
delL747-P753insS (Chung et al., 2012).  
Table 1: Best overall response to TKI therapy for tumors exhibiting varying exon 19 
deletions. Non-LRE deletions show the worst response to targeted therapy. Adapted from 
Chung et al., 2012. 
 
 
 However, despite the lower RR of non-LRE deletions, there was no statistically 
significant difference in PFS or OS between different deletion mutations (figure 10). This 
study shows that while different deletion mutations may affect response rates to TKI 
therapy, overall survival and PFS remains similar for all deletions. It is therefore prudent 
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to treat exon 19 deletions with targeted therapy, namely erlotinib, in the first-line setting. 
It is also important to note, non-LRE deletions are uncommon. Further investigation into 
this rare mutation class should be conducted in order to validate and confirm these 
results. 
 
Figure 10: Kaplan-Meier curves demonstrating (A) PFS and (B) OS for exon 19 
deletions. No significant difference is noted between varying exon 19 deletion mutations. 
Adapted from Chung et al., 2012 
 25 
 Interestingly, it appears tumors harboring exon 19 deletions are more responsive 
to targeted therapy than the other EGFR mutations currently known, including the L585R 
mutation. Mitsudomi et al., noted this in their literature analysis investigating the 
biological and clinical implications of EGFR mutations in lung cancer. In a compilation 
of 224 patient response rates, from various literature reports, to TKI therapy, patients 
with exon 19 deletions had an 84% response rate, as compared to 71% for L858R 
mutations. Furthermore, patients with L858R mutations experienced a much shorter mean 
survival time after TKI treatment than patients with exon 19 deletions (8 vs. 34 months, 
p<0.001)(Mitsudomi et al., 2006). Zhang et al. recently mirrored these results in their 
literature review.  
 Zhang et al. compiled data from a total of 13 studies and compared hazard ratios 
for PFS by indirect comparison for patients with exon 19 deletions or L858R mutations 
after first-line TKI therapy. They found patients with exon 19 deletions had a lower 
hazard ratio and an association with a longer PFS than patients with an L858R mutation 
(Zhang et al., 2014). Therefore, patients with exon 19 deletions may experience superior 
results with TKI treatment. However, the low number of studies used for their meta-
analysis is a significant limitation of this study. Additional studies with larger data sets 
and more convincing evidence will be needed to confirm this group’s hypothesis.      
IIb. Exon 19 Insertion: 
 
 Exon 19 insertions are a relatively newly discovered mutation within the EGFR 
tyrosine kinase domain. It is estimated they comprise 2% of all exon 19 mutations and 
1% of all EGFR mutations (He et al., 2012). Structural studies show this mutation occurs 
 26 
in the end of the β3 strand, in the N-terminus of the kinase domain, which lies adjacent to 
the αC helix. This mutation results in the addition of 6 amino acid residues to this area, 
extending the loop that connects to the αC helix (figure 7). Importantly, this results in the 
altered identity of Glu746 and Leu747. The alteration to Glue746 is varied and 
structurally of little significance, while Leu747 is consistently altered to proline and has 
structurally consequence. The change to proline alters the stabilizing hydrophobic 
interactions of this area and leads to an altered structural confirmation of the protein that 
favors activation (Ibid). This mechanism is a similar to the proposed mechanism as the 
L858R mutation, which occurs in a similar area of the protein (Yun et al., 2007). Until 
recently, exon 19 insertions sensitivity to TKI therapy was poorly described.  
 He et al., addressed this question by studying lung cancers harboring this mutation 
by examining structural effects, assessing in vitro sensitivity to TKIs, and assessed 
radiological response of patients receiving TKIs. In vitro, Ba/F3 cells transfected with 
exon 19 insertion mutations were found to be sensitive to both gefitinib and afatinib. 
Using Western blotting, the group assessed EHFR phosphorlyation, finding both gefitinib 
and afatinib inhibited EGFR phosphorylation in cells harboring exon 19 deletions. Of 
interesting note, the sensitivity of exon 19 insertions was less than that of exon 19 
deletions. The group identified 12 patients with exon 19 insertions. Of the 12, 4 received 
EGFR TKI in a palliative setting. Of the 4, 3 patients experienced a partial response by 
RECIST criteria, and 1 had a minor response, although to a novel EGFR TKI (He et al., 
2012). These results have been noted elsewhere in the literature, although reports have 
limited, mainly due to the rare occurrence of this mutation (Agbarya et al., 2014, Chan et 
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al., 2013, Otto et al., 2012). In addition to establishing exon 19 insertions as TKI 
sensitive, these studies also underscores the importance of using multi-platform assays in 
genomic testing in order to better characterize complex mutations in this patient 
population (Politi et al., 2012). Better characterization of these tumor’s genomics will 
allow clinicians to make better-informed decisions with regards to patient care. 
 These results demonstrate exon 19 insertions as responsive to TKI therapy, much 
like exon 19 deletions, with durable responses in the first-line setting. TKI therapy for 
these patients should therefore be prioritized as a first-line treatment.  
III. Exon 20 Mutations: 
 
 Exon 20 of EGFR translates amino acid positions 762 to 823, containing part of 
the αC helix (figure 11)(Yasuda et al., 2012). Exon 20 mutations are the third most 
common EGFR mutation described in the literature, comprising an estimated 3-10% of 
all reported cases (Mitsudomi et al., 2009, Oxnard et al., 2013). Despite their prevalence, 
relatively little is known about this type of EGFR mutation.  
IIIa. Exon 20 Insertions: 
 
 Exon 20 insertions are highly varied, and commonly are reported to occur after 
the αC helix and up to Cys775, although a small number (4%) have been discovered to 
affect residues within the αC helix (Yasuda et al., 2012). These insertions add 1-4 
residues to the end of the αC helix (Eck et al., 2009). In addition to being important for 
the ATP phosphotransfer, the αC helix’s position is important in determining an active or 
inactive confirmation (Walker et al., 1998). As seen with exon 19 deletions, which alter 
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the LRE fragment prior to the αC helix, exon 20 insertions are though to be able to push 
the αC helix into an inward confirmation by forming a “wedge” at the base of the C helix 
(Yasuda et al., 2013).  This change of confirmation renders the protein constitutively 
active. 
 
 
Figure 11: Schematic of Exon 20 with indications of all reported exon 20 insertion 
locations. Reported prevalence of each insertion is listed in parentheses next to the 
insertion. Adapted from Yasuda, 2012. 
 
 The frequency of exon 20 insertions is reported over a range, spanning 1 to 10%, 
although with a general consensus of 4-5% (Wu et al., 2008, Yasuda et al., 2012). This 
number may be inaccurate, as Oxnard et al., reports in their characterization of their 
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single-center experience with patients harboring exon 20 insertion mutations. They report 
a prevalence of 9.2%, which although may be referral bias, is likely due to the genotyping 
technique employed by prior studies (Oxnard et al., 2013). Using a non-specific 
mutational assay, they argue, will be essential in order to not miss mutations usually 
overlooked by mutation specific assays. 
 Unlike classic EGFR mutations, G719X, exon 19 deletions, and L858R, exon 20 
insertions are not predictive of TKI sensitivity. In both preclinical and clinical models, 
resistance to TKI therapy was observed, despite occurring in patient populations with 
similar characteristics as other mutations (Wu et al., 2008, Greulich et al., 2005, Sasaki et 
al., 2007, Yasuda et al., 2013). Oxnard et al. support this last finding in their review of 
patients at their center. The group reviewed cases of 1086 patients who had undergone 
conclusive EGFR genotyping. Of the 1086, 294 were identified with EGFR mutations, 27 
of which harbored EGFR exon 20 insertion mutations. Survival analysis performed on 
839 patients showed patients harboring exon 20 insertions had a median survival of 16.5 
months (95% CI: 10.4-NA); poorer than patients with common mutations, who 
experienced median survival rates of 33.0 months (95% CI: 28.7-40.6). Interestingly, 
patients with exon 20 insertions fared similarly to patients with WT EGFR (figure 
12)(Oxnard et al., 2013).  
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Figure 12: Survival of patients from date of advanced disease. The survival curves 
show exon 20 insertions have a poorer median survival than common EGFR mutations, 
but similar survival rates to patients with WT EGFR mutational status. Adapted from 
Oxnard et al., 2013. 
 
The results from this review are supported by several other studies, all which show exon 
20 insertions confer decreased sensitivity to TKI treatment of both first generation 
reversible and second generation, irreversible inhibitors (Yasuda et al., 2012, Sasaki et 
al., 2007). Due to this, it has become common practice to restrict patients with exon 20 
insertions from clinical trials exploring the activity of novel TKIs. It has therefore 
become necessary to develop mutation specific targeted therapies for this subgroup of 
patients.  
 One such drug that has shown moderate promise is AUY922, a heat shock protein 
90 (HSP90) inhibitor, which shows clinical activity in patients harboring the exon 20 
mutation. AUY922 works by disrupting HSP90, which helps stabilize other proteins 
required in cell survival processes. AUY922 was first noted to have anti-cancer activity 
in a prior trial, NCT01124864, with one patient experiencing a durable partial response 
by RECIST criteria. Investigators designed a phase II trial, currently ongoing, to further 
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explore AUY922’s clinical activity (Piotrowska et al., 2015). So far, the study has 
enrolled 15 patients in the second stage. Of those 15 patients, 3 have achieved a 
confirmed partial response by RECIST criteria and an additional 7 have experienced 
durable stable disease, with an overall PFS of 6.1 months (95% CI, 1.2 to NR)(figure 
13)(Piotrowska et al., 2015). Importantly, the drug is well tolerated with reversible grade 
1 toxicities. 
Figure 13: Overall PFS for patients under AUY922 treatment. Median PFS has been 
established as 6.1 months. Adapted from Piotrowska et al., 2015. 
 
This is the first study designed and executed that specifically targets patients with EGFR 
exon 20 insertions. Initial data suggests AUY922 may be a viable treatment option for 
patients with this mutation, with patients currently experiencing a median PFS of 6.1 
months and low toxicity. Further study of AUY922 is therefore warranted in this 
population to determine if it should replace current standard therapies for these patients. 
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 Until the story of AUY922 becomes more developed, treatment with standard 
chemotherapy is the best available option for these patients. A recent retrospective study 
supports this clinical decision. Naidoo et al. identified 1,882 patients, 46 of which had 
EGFR exon 20 insertions. The majority of these patients did not respond to EGFR TKI 
therapy, but did experience moderately high response rates to chemotherapy, most 
effectively platinum based doublet therapy (Naidoo et al., 2015). Similar results were 
noted in previous studies (Oxnard et al., 2013). The conclusion should therefore be made 
standard chemotherapy, most likely platinum-based doublet chemotherapy, should be 
used to treat patients who present with metastatic EGFR exon 20 insertion mutations in 
the first-line setting. 
IIIb. Exon 20 A763_Y764insFQEA Insertion:  
 
 One variant of an exon 20 insertion, specifically the A763_Y764insFQEA, an in-
frame insertion, occurring with a frequency of approximately <1%, has been shown to 
confer increased sensitivity to TKI treatment (Costa, 2014). Yasuda et al., unexpectedly 
found this mutation is highly sensitive to TKI in vitro and in patients whose tumor 
harbors this specific insertion. The group postulates this specific insertion, located within 
the C helix, shifts the C helix toward its N-terminus, altering the length of the β3-αC 
loop, and causing a I759A replacement. These changes are at the site of exon 19 deletions 
and L858R and L861 mutations, respectively. Therefore, this specific insertion may 
resemble exon 19 deletions and L858R mutations more closely than its fellow exon 20 
insertions. In their experience, three patients with an EGFR A763_Y764insFQEA 
insertion, had clinical and radiological regressions or stable disease while on TKI therapy 
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(Yasuda et al., 2013). In vitro and clinical data, therefore suggests, while patients with 
EGFR exon 20 insertions be treated with standard platinum-doublet chemotherapy, 
patients with the specific EGFR A763_Y764insFQEA insertion should be treated 
preferentially with EGFR TKI therapy. 
IV. Exon 21 Mutations: 
 Exon 21 point mutations are the other most common somatic EGFR mutations, 
comprising, along with exon 19 deletions, approximately 86% of all EGFR mutations 
reported. The two most commonly reported exon 21 mutations are L858R mutations and 
L861Q mutations, with an occurrence of 43% and 2%, respectively (Lovly, 2015). Both 
of these mutations increased phosphorlyation of EGFR in the absence of ligand 
stimulation (Mitsudomi et al., 2010). Due to the high rate of occurrence, exon 21 point 
mutations, specifically L858R mutations, have been extensively studied.  
IVa. Exon 21 L858R Mutation: 
 
 The exon 21 L858R mutation is a thymine to guanine transversion point mutation 
that results in the replacement of leucine at position 858 with an arginine residue (Riley 
et al., 2006). The mutation occurs at the N-terminus of the helical turn in the activation 
loop in the inactive confirmation of the protein (figure 7)(Eck et al., 2010)(Yun et al., 
2007). This area of the activation loop is integrated with a hydrophobic grouping of 
residues, which hold the C helix in an inactive confirmation. The positively charged 
arginine residue destabilizes this confirmation, forcing the protein into its active 
confirmation. Interestingly, it appears the arginine residue also forms a hydrogen bond 
 34 
with the arginine residue at position 836, further stabilizing the protein in an active 
confirmation (Yun et al., 2007). This structural analysis provides valuable insight in how 
L858R mutations affect the confirmation of the EGFR protein.  
 Exon 21 L858R mutations have a reported occurrence of 43%, making them one 
of the most common EGFR mutations (Mitsudomi et al., 2010). Like exon 19 deletions 
and exon 18 G719X mutations, they exhibit sensitivity to inhibition by TKI therapy, both 
in vivo and in vitro (Paez et al., 2004, Rosell et al., 2012). These results have been 
confirmed by multiple studies within the last few years.  
 As noted above, the OPTIMAL study conducted by Zhou et al., demonstrated 
superior results for patients harboring activating mutations (exon 19 deletions or L858R 
mutations) treated with targeted therapy versus standard chemotherapy (PFS 13.1 versus 
4.6 months, CI 95%, HR = 0.16)(Zhou et al., 2011). Wu et al., reported similar results 
with the LUX-Lung 6 trial, an open label, phase III trial comparing afatinib with cisplatin 
plus gemcitabine in first-line, EGFR mutant positive Asian patients. The majority of 
patients harbored exon 19 deletion (51%) or L858R mutations (37%). 364 patients were 
randomized in a 2:1 ratio to the afatinib arm or standard chemotherapy arm, respectively. 
By independent-central review, patients who received targeted therapy experienced 
increased PFS over patients treated with standard chemotherapy (11.0 versus 5.6 months, 
CI 95%, HR = 0.28)(figure 14)(Wu et al., 2012). Additionally, a greater percentage of 
patients receiving afatinib reached objective response (66.9% versus 23.0%). They also 
reached an objective response quicker than patients receiving standard chemotherapy (By 
6 weeks, 49.2% versus 13.1%).  
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Figure 14: Independent-central review of overall PFS for patients receiving afatinib 
versus standard chemotherapy. Patients randomized to the afatinib arm experienced a 
significantly longer PFS compared to those patients on standard chemotherapy. Adapted 
from Wu et al., 2012. 
 
 Importantly, tolerable toxicity was also noted in the experimental treatment group. 
The main toxicities noted in the experimental group were rash (14.6%), diarrhea (5.4%), 
and stomatitis (5.4), while in the control arm neutropenia (26.5%), vomiting (19.5%), and 
leukopenia (15.0%) were most common. These results demonstrate targeted therapy in 
the first-line setting, significantly improves PFS with tolerable toxicity profile for Asian 
patients whose tumor is EGFR mutant positive. 
 These results have also been replicated in non-Asian populations. Rosell et al. 
noted the superior response to targeted therapy in their prospective trial of Spanish 
patients (Rosell et al., 2009). They screened 2105 patients with NSCLC for EGFR 
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mutations. Of the 2105 patients screened, 350 tested positive for EGFR mutations. Of the 
350 patients identified, 217 received erlotinib, of which 197 were evaluated for a 
response. A majority of patients had clinical characteristics concurrent with those 
previously reported (adenocarcinoma, women, never-smokers), although the group notes 
unintentional selection bias may be responsible. Patients receiving erlotinib in the first 
line setting experienced a median PFS of 14 months, an increase compared to previously 
reported PFS of patients on standard chemotherapy (Schiller et al., 2002). These results 
prompted the group to undertake the aforementioned phase III EURTAC study, which 
demonstrated targeted therapy as superior to standard chemotherapy for non-Asian 
patients with exon 19 deletions or L858R mutations in the first line setting (Rosell et al., 
2012). The results from these studies established firmly, targeted therapy should 
preferentially be utilized in the first-line setting for both Asian and non-Asian patients 
whose tumors harbor exon 21 L858R mutations.  
 While both exon 19 deletions and L858R mutations confer sensitivity to TKI 
therapy, as noted previously, L858R mutations have lower response rates to therapy. This 
has been shown by multiple groups (Jackman et al., 2009, 2012, Goto et al., 2013, 
Mitsudomi et al., 2005, Riley et al., 2006). In a recent pooled analysis of the LUX-Lung 3 
and LUX-Lung 6 trials, both examining the affect of afatinib versus standard 
chemotherapy for EGFR mutant positive patients, Yang et al. demonstrated patients with 
exon 19 deletions experienced a statistically significant increase in overall survival 
compared to patients on standard chemotherapy (Yang et al., 2015). This survival 
advantage was not extended to patients with exon 21 L858R mutations, however. The 
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reasons for this are still unclear. It may be due to the specific structural changes each 
mutation inflicts upon the kinase region of the EGFR protein. Exon 19 deletions may 
alter the confirmation of the ATP binding region in a way that makes the area more 
conducive to binding with TKIs. Additionally, L858R mutations may be more commonly 
associated with other mutations, which may affect the way in which TKIs bind to EGFR 
(Mitsudomi et al., 2007). Additional research is needed to further elucidate why exon 19 
deletions have better response to TKI therapy than exon 21 L858R mutations. 
 While these reasons may explain the differential in drug sensitivity conferred by 
exon 19 deletions or exon 21 L858R mutations, patients whose tumors harbor exon 21 
L858R mutations benefited significantly from treatment with TKI compared to standard 
chemotherapy, thus establishing TKI therapy as the preferred treatment choice for this 
patient population in the first-line setting. 
IVb. Exon 21 L861Q Mutation:  
 
 The exon 21 L861Q mutation is an amino acid substitution of glutamine for 
leucine at position 861 in EGFR. It is considered a rare mutation, with a reported 
occurrence of only 2% (Lovly, 2015). Exon 21 L861Q mutations also occur in the 
activation loop of the EGFR tyrosine kinase and, similarly to exon 21 L858R mutations, 
may disrupt the hydrophobic interactions of that area, thus forcing the protein into an 
ever-active confirmation. 
 Despite the paucity of this mutation, it has been determined exon 21 L861Q 
mutations confer sensitivity to TKI therapy (Lynch et al., 2004). Additional research 
confirms this finding by Lynch et al., but also illuminates the effect of TKI on this 
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specific mutation further. It has been noted by various groups that while this mutation is 
sensitive to TKI treatment, as is the case for other rare EGFR mutations, it is less 
responsive than the “classic” EGFR mutations of exon 19 deletions and exon 21 L858R 
mutations (Lohinai et al., 2015, Chiu et al., 2015, Watanabe et al., 2014, Wu et al., 2011). 
Lohinai et al. compiled 814 lung adenocarcinoma patients with KRAS and/or EGFR 
mutations, analyzing 419 for clinical outcome. They identified 49, or 6%, as rare 
mutations, including L861Q mutations. Interestingly, a majority of rare mutations 
identified were significantly correlated to smoking history. The group also noted patients 
with previously identified sensitizing rare mutations (G719X and L861Q) experienced 
higher response rates to TKI than patients with other rare mutations. Perhaps 
unsurprisingly, the group noted patients harboring rare mutations experienced a 
significantly shorter TKI response rate compared to patients with defined classic EGFR 
mutations (71% versus 37%, p = 0.039). These results were mirrored by the work of Chiu 
et al. The results from these studies indicate patients with these mutations should still be 
considered for TKI therapy, and highlight the importance of comprehensive genomic 
testing for patients in this setting. 
 Watanabe et al. performed a post hoc analysis of the NEJ002 trial, a randomized 
phase III trial comparing gefitinib to standard chemotherapy in chemo naïve patients, 
demonstrating results similar to Lohinai and Chiu. They show patients with rare EGFR 
mutations fare worse with TKI therapy compared to patients with common EGFR 
mutations in terms of overall survival (figure 15). The group also noted a similar 
relationship with regards to PFS. 
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Figure 15: Kaplan-Meier plot of overall survival for patients with rare or common 
mutations after treatment with gefitinib. The plot highlights to significantly lover 
overall survival for patients with rare mutations treated with targeted therapy, compared 
to patients harboring common mutations. The low number of patients with rare mutations 
(5) should be noted as a limitation of this analysis. Adapted from Watanabe, 2014. 
 
Due to the rarity of this mutation, it has been hard to establish a first line therapy for 
patients with this mutation. In vitro and in vivo studies have shown sensitivity to 
treatment with TKI, albeit with reduced response rates compared to more common EGFR 
mutations. However, there remains uncertainty about the role of TKI therapy in the 
clinical course of these patients, with some groups arguing first-line chemotherapy may 
be most beneficial for this patient population (Watanabe et al., 2014). Other groups report 
promising response rates with treatment of irreversible TKI, such as afatinib (Yang et al., 
2013). Yang et al. presented their analysis of data from the LUX-Lung 2, 3 and 6 trials, 
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focusing on patients who were identified as harboring rare mutations. The group noted 
promising PFS and OS for patients with L861Q mutations. Based on these results, 
treatment of exon 21 L861Q mutations, and rare mutations in general, with afatinib may 
be an appropriate clinical decision.  
 At this time, there is still insufficient data to define a first-line treatment for 
patients with exon 21 L861Q mutations. Most published information on this mutation is 
reports of small sample size or case reports, the results of which are often controversial or 
contradictory. Current understanding indicates this mutation confers sensitivity to 
treatment with TKI, and there has been reports of promising response using irreversible 
inhibitors like afatinib. Despite this, due to the limited information currently available, it 
is advised patients with this mutation be assessed individually, although treatment with 
TKIs should be considered, as they have shown to be beneficial in the past. Additional 
research, and compilation of data from various centers will help to further understanding 
of this mutation and elucidate a more concrete treatment course for this subset of patients.  
V. Resistance Mutations: 
 
 Patients who present with NSCLC with activating EGFR mutations, particularly 
exon 19 deletions and exon 21 L858R mutations, show remarkable responses to TKI 
therapy, especially compared to standard chemotherapy (Mok et al., 2009, Mitsudomi et 
al., 2010). Unfortunately, despite marked response to these drugs, patients almost 
unequivocally develop acquired resistance and subsequent tumor progression, limiting 
the long-term potential of TKI therapy (Tartarone et al., 2015). Resistance occurs 
approximately 1 to 2 years after initiation of TKI therapy, with the majority of resistance 
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mutations revealing themselves as T790M mutations, with an occurrence of 50 to 60% at 
re- biopsy (Acrila et al., 2011). Other mechanisms of resistance include MET 
amplification, phenotypic and other point mutations, and interestingly, histological 
transformation to SCLC (Politi et al., 2015, Rosell et al., 2012). There is a great clinical 
need to address these emerging resistance mutations in order to provide better, more 
effective treatments for patients once these mutations are acquired. Due to its high 
prevalence in this patient population, extensive work has been done to understand and 
treat T790M mutations. 
Va. T790M Mutations: 
 
 The T790M mutation is located in exon 20 and is resultant of a base change from 
cytosine to thymine, which codes for the substitution of methionine for threonine at 
position 790 in the catalytic cleft of the EGFR tyrosine kinase domain (figure 
8)(Kobayashi et al., 2005). Structural modeling shows this substitution affects erlotinib 
binding in the ATP domain by, one, introducing a bulkier amino acid into the region 
possibly causing steric inference and, two, removing a hydrogen bond interaction 
between erlotinib and threonine which likely contributed to erlotinib’s previous high 
affinity to the binding site (Pao et al., 2005). T790M have similar interfering affects on 
gefitinib as well. While T790M mutations affect the ATP binding site of the EGFR 
tyrosine kinase domain, it is not expected to alter the ability of ATP binding to the 
domain, and therefore the activity of the kinase in general, meaning EGFR inhibition may 
still be a viable therapeutic option (Kobayashi et al., 2005, Ohashi et al., 2013).   
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 Clinically, T790M mutations in exon 20 have been suggested to be associated 
with indolent growth characteristics and a longer PFS. The prognosis for patients with 
T790M mutations is better than patients without the mutation, although this may be 
reflective of other resistance mutations present in T790M negative tumors. Interestingly, 
T790M mutations are also more likely to occur in an existing site of disease (Chmielecki 
et al., 2011, Oxnard et al, 2011). While most T790M mutations are noted post-
progression, a small subset of approximately 1 to 2% of cases is detected de novo. These 
cases usually display decreased sensitivity to EGFR TKI therapy and occur in conjuction 
with other sensitizing EGFR mutations (Wu, 2011). Of this group of patients, 
approximately 50% of them harbor germline T790M mutations (Oxnard et al, 2013). This 
is of high importance, as patients with germline T790M mutations should receive familial 
testing so to establish appropriate screening measures for early detection of disease. The 
issue of resistance by the T790M mechanism, both pre and post treatment, provides an 
interesting challenge to the treatment and management of disease in this patient 
population. 
 Afatinib, as a potent irreversible TKI, has shown preclinical and clinical activity 
against T790M mutations (Miller et al., 2012, Katakami et al., 2013, Soca et al., 2012, Li 
et al., 2008). Despite its demonstrated activity against T790M, it has a high frequency of 
gastrointestinal and skin toxicity that limits its usefulness in clinical settings. However, 
preclinical findings indicate the combination of afatinib and cetuximab lead to dramatic 
response of tumors harboring T790M mutations (Regales et al., 2009). Based on these 
findings, Janjigian et al. conducted a study to explore the efficacy and safety of afatinib 
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and cetuximab in combination for patients who met criteria for acquired resistance as 
proposed by Jackman et al. (Jackman et al., 2010, Janjigian et al., 2014). Patients were 
allowed to continue EGFR TKI therapy past progression to limit risk of disease flare 
(Chaft et al., 2013). The dual blockade of EGFR by afatinib and cetuximab, in this study, 
demonstrated a strong and durable response, with an objective response rate of 29%. 
Gomes and Cruz reported two cases in which patients with T790M mutated NSCLC 
reached partial responses with treatment of afatinib and cetuximab in combination further 
extending the results reported by Jnjigian et al. (Ribeiro Gomes and Cruz, 2015). 
Interestingly, response rates were similar for both T790M positive and negative patients. 
Additionally important, the combination demonstrated a somewhat manageable toxicity 
profile with rates of grade 3 and 4 therapy related adverse events of 44% and 2% 
respectively. This combination represents a viable treatment option for heavily pre-
treatment patients who have developed resistance after prior TKI therapy. 
 More recently, third generation TKI drugs have entered clinical trial testing, 
emerging as potentially effective treatments for patients whose tumors have developed 
T790M resistance. Two of these third generation TKIs are AZD9291 and rociletinib (CO-
1686).  
 AZD9291 is an oral, irreversible EGFR TKI that is selective for common 
sensitizing mutations as well as the T90M resistance mutation. In preclinical models it 
showed significantly lower activity against wild-type EGFR and higher activity against 
T790M tumors than previously demonstrated by afatinib (Cross et al., 2014). In a phase I 
study to determine the efficacy and safety of AZD9291 in patients with advanced EGFR 
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mutated NSCLC with acquired resistance to EGFR TKI therapy, Jänne et al. found 
AZD9291 to have potent activity against T790M mutated NSCLC. 138 patients harbored 
a centrally detected T790M mutation, of which 127 could be evaluated for a response. Of 
these patients, there was a 61% rate of achieved objective response and a 95% disease 
control rate (figure 16). Disease control is defined as the percentage of patients who 
experience, as defined by RECIST criteria, stable disease, partial response, or complete 
response. Of the patients with a detected T790M mutation, the median PFS was 9.6 
months (figure 17)(Jänne et al., 2015). Interestingly, although not surprising based on 
AZD9291’s preclinical activity against wild-type EGFR, AZD9291 has a very 
manageable toxicity profile, with limited skin and gastrointestinal side effects, especially 
in comparison to afatinib and cetuximab combination therapy.  
 
Figure 16: Waterfall plot of EGFR T790M positive response to AZD9291. Overall 
61% of patients in the T790M positive sub group achieved objective response. Of note, 
patients from all dosing level cohorts experienced objective response. Adapted from 
Jänne et al, 2015. 
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Figure 17: Kaplan-Meier plot of PFS of T790M positive patients versus T790M 
negative patients. T790M positive patients demonstrated a median PFS of 9.6 months, 
compared to median 2.8 months for patients with no detectable T790M mutation. 
Adapted from Jänne et al, 2015. 
  
 With a response rate and PFS that nearly doubles that of afatinib and cetuximab in 
a T790M mutated NSCLC patient population, with a much more manageable toxicity 
profile, AZD9291 appears to be a potent therapy for patients with this mutation.  
 While the above results were achieved with patients who had previous exposure 
to EGFR TKI, AZD9291 was also utilized in treatment naïve patients. Presented by 
Ramalingam et al, results from the treatment naïve cohort of the AZD9291 phase I study 
show positive results from treatment with AZD9291 in a treatment naïve patient 
population (Ramalingam et al., 2015). FLAURA, a trial comparing AZD9291 to erlotinib 
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or gefitinib in EGFR mutant treatment naïve patients, is currently underway and will 
explore if AZD9291 is superior to first generation TKIs in a first-line setting.  
 Rociletinib (CO-1686) is another third generation EGFR TKI, also with 
impressive results in current clinical trials. Rociletinib is an EGFR selective, oral, 
irreversible inhibitor that has shown preclinical activity against common EGFR mutations 
as well as T790M resistance mutations (Walter et al., 2014). Strucutal models show 
rociletinib covalently binds to the cysteine at position 797, modifying the ATP binding 
site, resulting in inhibition of the tyrosine kinase domain (figure 18). It, like AZD9291, 
spares EGFR wild-type.  
 
Figure 18: Structural model of rociletinib bound to EGFR T790M. Covalently 
binding to Cys797 places rociletinib in position to inhibit the mutated tyrosine kinase. 
Adapted from Walter, 2014 
 
 In a clinical setting, rociletinib exhibited strong efficacy in EGFR T790M positive 
tumors with a response rate of 59% and an estimated median PFS of 13.1 months. 93% of 
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patients experienced disease control (figure 19)(Sequist et al., 2015). As seen with 
AZD9291, again explained by the selective nature of the inhibitor, there was infrequent 
and controllable skin and gastrointestinal adverse events. The most common grade 3 
adverse event experienced was hyperglycemia, which occurred at a rate of 22%. No 
patients discontinued treatment due to this adverse event and were treated with success 
by dose reduction or a hypoglycemic agent, usually metformin.  
 
Figure 19: Waterfall plot of rociletinib’s activity against EGFR T790M positive 
tumors. Overall objective response rate of patients in this subgroup was 59%. Adapted 
from Sequist et al., 2015. 
  
 Preclinical studies show a metabolite of rociletinib is what causes hyperglycemia 
through inhibition of type I IGF-IR. Interestingly, activation of this pathway has been 
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proposed as a resistance mechanism to EGFR inhibition. It is currently unknown if 
rociletinib’s inhibitory nature on this pathway contributes to the drug’s efficacy in EGFR 
TKI resistance NSCLC. 
 A major limitation of this study is the limited number of patients to receive study 
drug, a result of the design of the study. Larger studies are currently underway and are 
essential to confirm the results of this striking, yet small study. 
 Additional studies will further elucidate the activity of AZD9291 and rociletinib, 
and are needed to verify the results discussed above. Both drugs display selective, potent 
activity against EGFR T790M mutated NSCLC. However, with rociletinib’s tendency to 
induce hyperglycemia in patients, patients who have a comorbidity of diabetes, or who 
are pre-diabetic, perhaps should be preferentially steered toward treatment with 
AZD9291 in this setting. Regardless, both AZD9291 and rociletinib exemplify major 
steps forward in the treatment of resistance acquired, EGFR mutated NSCLC. Both 
therapies will extend overall survival of this patient population, and do so with less 
toxicity than previous treatments. The presence of T790M mutations in patient’s tumors 
therefore present a targetable biomarker, reinforcing the importance of obtaining tumor 
samples post progression on EGFR TKI therapy.  
Vb. MET Amplification:  
 
 MET amplification is an alternative resistance mechanism that occurs in 
approximately 20% of patients in the acquired resistance setting. The MET is a proto-
oncogene that encodes a heterodimeric transmembrane receptor kinase. Binding of the 
receptor to its ligand activates dimerization leading to increased tyrosine kinase activity. 
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This can activate multiple downstream pathways, including those responsible for cell 
growth and survival (Bean et al., 2007). MET amplification, therefore, can bypass EGFR 
signaling, to activate secondary messengers downstream of EGFR, rendering EGFR TKIs 
ineffectual. In studies conducted by Bean et al., they identified MET amplification in 
21% of samples of EGFR mutant NSCLC that had acquired resistance to EGFR TKI 
therapy. Interestingly, 40% of these samples also harbored the EGFR T790M mutation, 
demonstrating these mutations can occur within the same cells. Engleman et al. noted 
similar results, identifying MET amplification in 22% of lung cancer samples that had 
developed resistance to EGFR TKIs (Engleman et al, 2007). It has been established, 
EGFR TKI resistance can be overcome by treatment of MET amplified tumors with 
EGFR and MET inhibitors (Turke et al., 2011). This has set the stage for combination 
therapies, specifically with third generation TKIs. With their well-tolerated toxicity 
profiles, agents like AZD9291 and rociletinib are attractive agents to use in combination 
therapy with MET inhibitors to address EGFR TKI resistance by MET amplification 
mechanisms. Trials are currently underway to explore this as a treatment option for these 
patients.  
 One such trial is the TATTON trial, a multi-arm, phase 1b trial of AZD9291 
combined with AZD6094, selumetinib (both MET inhibitors) or MEDI4736, an anti-PD-
L1 monoclonal antibody. Preliminary results suggest the toxicity profile of combination 
therapy with EGFR and MET inhibitors is tolerable in patients. Furthermore, in the 
selumetinib and AZD6094 treatment arms, there is a reported partial response in 9 of 23 
and 6 of 11 patients, respectively (Oxnard et al., 2015). These preliminary results suggest 
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combination therapy is tolerated and has a high efficacy in patients with MET 
amplification resistance. A final analysis of this study once it is completed will allow 
greater insight into the role of combination EGFR/MET inhibitors in treating EGFR TKI 
resistance in this patient population. Further studies will also be needed to expand upon 
and verify the results of this trial.  
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CONCLUSIONS AND FUTURE DIRECTIONS 
 With the discovery and implementation of targeted therapies, especially in the 
setting of EGFR mutated NSCLC introduced a paradigm shift in how these cancers were 
approached and treated by physicians. The influx of investigation into these mutations 
have greatly increased the medical communities understanding of the underlying 
mechanisms of EGFR mutated driven NSCLC and has led to the development of first, 
second, and third generation EGFR TKI therapies that have improved patient lives and 
extended overall survival. Unfortunately, these cancers continue to develop resistance to 
targeted therapies designed to curtail their affect on cell growth and proliferation. Even 
with third generation inhibitors, like AZD9291, resistance has started to appear in the 
form of a novel EGFR C797S mutation, adding further to the complexity of the situation 
and presenting yet additional challenges to researchers and clinicians alike (Thress et al., 
2015).  
 As the story of EGFR mutated NSCLC continues to evolve, it continues to 
highlight the importance of understanding the molecular mechanisms of cell signaling in 
this setting, obtaining and sequencing patient tissue post progression to determine any 
targetable mutations that may have developed, and the ever growing complexity 
researchers and clinicians face in their efforts to provide safe and efficacious therapies to 
patients afflicted with this disease.  
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APPENDIX 
Timeline of Important EGFR related Discoveries (Chong, Jänne, 2013) 
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